The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies.
Leonard Joseph Appleman
No relevant relationships to disclose
Jan Hendrik Beumer
No relevant relationships to disclose
Yixing Jiang
No relevant relationships to disclose
Shannon Puhalla
No relevant relationships to disclose
Yan Lin
No relevant relationships to disclose
Taofeek Kunle Owonikoko
No relevant relationships to disclose
R Donald Harvey
No relevant relationships to disclose
Ronald Stoller
No relevant relationships to disclose
Daniel P. Petro
No relevant relationships to disclose
Hussein Abdul-Hassan Tawbi
No relevant relationships to disclose
Athanassios Argiris
Consultant or Advisory Role - Abbott Laboratories
Sandra Strychor
No relevant relationships to disclose
Brian Kiesel
No relevant relationships to disclose
Edward Chu
No relevant relationships to disclose
Stacie Peacock Shepherd
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Vincent L. Giranda
Employment or Leadership Position - Abbott Laboratories
Stock Ownership - Abbott Laboratories
Alice P. Chen
No relevant relationships to disclose
Chandra Prakash Belani
No relevant relationships to disclose
Suresh S. Ramalingam
Consultant or Advisory Role - Abbott Laboratories